Cargando…

Peripheral serotonin-mediated system suppresses bone development and regeneration via serotonin 6 G-protein-coupled receptor

Serotonin is important in brain functions and involved in neurological diseases. It is also drawn considerable attention in bone disease since it mainly produced by the gut. Serotonin 6 G-protein-coupled receptor (5-HT(6)R) is clinical targets for the treatment of neurological diseases. However, 5-H...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Hyung-Mun, Park, Kyung-Ran, Hong, Jin Tae, Kim, Eun-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007490/
https://www.ncbi.nlm.nih.gov/pubmed/27581523
http://dx.doi.org/10.1038/srep30985
Descripción
Sumario:Serotonin is important in brain functions and involved in neurological diseases. It is also drawn considerable attention in bone disease since it mainly produced by the gut. Serotonin 6 G-protein-coupled receptor (5-HT(6)R) is clinical targets for the treatment of neurological diseases. However, 5-HT(6)R as a therapeutic target in bone has not been reported. Herein, we found that 5-HT(6)R showed higher expression in bone, and its expression was increased during bone remodeling and osteoblast differentiation. The activation of 5-HT(6)R by ST1936 caused the inhibition of ALP activity and mineralization in primary osteoblast cultures, which was antagonized by SB258585, an antagonist and by the knockdown of 5-HT(6)R. Further investigation indicated that 5-HT(6)R inhibited osteoblast differentiation via Jab1 in BMP2 signaling but not PKA and ERK1/2. In vivo studies showed that the activation of 5-HT(6)R inhibited bone regeneration in the calvarial defect mice and also delayed bone development in newborn mice; this response was antagonized by SB258585. Therefore, our findings indicate a key role of 5-HT(6)R in bone formation through serotonin originating in the peripheral system, and suggest that it is a novel therapeutic target for drug development in the bone repair and bone diseases.